Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Source: SeekingAlpha
2026-03-03 13:50:10 ET
The last time I spoke about Prothena Corporation plc ( PRTA ), it was in a Seeking Alpha article entitled " Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place ." I went over two of its main clinical programs, which were the use of monoclonal antibodies to treat patients with neurodegenerative disorders. One program involves the company partnering with Roche ( RHHBY ) to evaluate the use of anti-alpha-synuclein antibody prasinezumab for the treatment of patients with early-stage Parkinson's Disease [PD] in the ongoing phase 3 PARAISO study....
Read the full article on Seeking Alpha
For further details see:
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Bristol-Myers Squibb Company
NASDAQ: BMY
BMY Trading
0.33% G/L:
$59.135 Last:
3,589,652 Volume:
$59.67 Open:
BMY Latest News
March 09, 2026 06:59:00 am
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
BMY Stock Data
$123,325,918,376
2,034,328,000
N/A
1394
N/A
Pharmaceuticals
Healthcare
US
Princeton
